VACCITECH (SP.ADR)/1 Total Liabilities
VACCITECH (SP.ADR)/1 total liabilities. Based on the latest financial reports, VACCITECH (SP.ADR)/1 (2AB) has total liabilities worth €25.66 Million EUR (≈ $30.01 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See 2AB cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of VACCITECH (SP.ADR)/1 (2021–2025)
Total liabilities of VACCITECH (SP.ADR)/1 from 2021 to 2025. This chart illustrates how VACCITECH (SP.ADR)/1's total liabilities have evolved over time, based on quarterly financial data.
VACCITECH (SP.ADR)/1 Competitors by Total Liabilities
The table below lists competitors of VACCITECH (SP.ADR)/1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Agung Semesta Sejahtera Tbk PT
JK:TARA
|
Indonesia | Rp42.24 Billion |
|
MegaMD Co. Ltd
KQ:133750
|
Korea | ₩16.86 Billion |
|
Nova Agritech Ltd.
NSE:NOVAAGRI
|
India | Rs-2.33 Billion |
|
Pure Hydrogen Corporation Ltd
AU:PH2
|
Australia | AU$10.49 Million |
|
HYUNGJI INNOVATION & CREATIVE Co.Ltd
KQ:011080
|
Korea | ₩25.13 Billion |
|
Bangsaphan Barmill Public Company Limited
BK:BSBM
|
Thailand | ฿20.36 Million |
|
Lithium Energy Ltd
AU:LEL
|
Australia | AU$2.64 Million |
|
Zuleika Gold Ltd
AU:ZAG
|
Australia | AU$2.06 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down VACCITECH (SP.ADR)/1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 2AB asset base.
Liquidity & Leverage Metrics
VACCITECH (SP.ADR)/1 Total Liabilities Ratios Explained
VACCITECH (SP.ADR)/1 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how VACCITECH (SP.ADR)/1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for VACCITECH (SP.ADR)/1 (2021–2025)
The table below shows the annual total liabilities of VACCITECH (SP.ADR)/1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €23.88 Million ≈ $27.91 Million |
-20.92% |
| 2024-12-31 | €30.19 Million ≈ $35.30 Million |
+9.75% |
| 2023-12-31 | €27.51 Million ≈ $32.16 Million |
+1.88% |
| 2022-12-31 | €27.00 Million ≈ $31.57 Million |
-4.08% |
| 2021-12-31 | €28.15 Million ≈ $32.91 Million |
-- |
About VACCITECH (SP.ADR)/1
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targetin… Read more